









市场行情
/
股票
/
nasdaq-srzn
/

Surrozen Inc

SRZN

23.000USD

+1.240+5.70%

收盘 12/22, 16:00（美东）报价延迟15分钟

197.13M总市值

亏损市盈率 TTM



Surrozen Inc

23.000

+1.240+5.70%

概览公司财务分析

概览

公司

财务

分析

关于 Surrozen Inc 公司

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

Surrozen Inc简介



公司代码SRZN

公司名称Surrozen Inc

上市日期Nov 23, 2020

CEOParker (Craig C)

员工数量40

证券类型Ordinary Share

年结日Nov 23

公司地址171 Oyster Point Blvd

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16504752820

网址https://www.surrozen.com

公司代码SRZN

上市日期Nov 23, 2020

CEOParker (Craig C)

Surrozen Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Yang Li, Ph.D.

Executive Vice President - Research

13.74K

+3.00%

Mr. Charles O. Williams

Chief Operating Officer, Corporate Secretary

9.38K

+4.45%

Dr. Mary Haak-Frendscho, Ph.D.

Independent Director

2.34K

Dr. Shao-Lee Lin, M.D., Ph.D.

Independent Director

2.34K

Dr. Anna Berkenblit, M.D.

Independent Director

2.34K

Mr. Christopher Y. Chai

Independent Director

2.34K

Dr. Mace Rothenberg, M.D.

Independent Director

2.34K

Mr. Eric H. Bjerkholt

Independent Director

Dr. David J. Woodhouse, Ph.D.

Independent Chairman of the Board

Mr. Craig C. Parker

President, Chief Executive Officer, Director

名称

名称/职务

职务

持股

持股变动

Mr. Yang Li, Ph.D.

Executive Vice President - Research

13.74K

+3.00%

Mr. Charles O. Williams

Chief Operating Officer, Corporate Secretary

9.38K

+4.45%

Dr. Mary Haak-Frendscho, Ph.D.

Independent Director

2.34K

Dr. Shao-Lee Lin, M.D., Ph.D.

Independent Director

2.34K

Dr. Anna Berkenblit, M.D.

Independent Director

2.34K

Mr. Christopher Y. Chai

Independent Director

2.34K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

The Column Group LP

21.60%

StemPoint Capital LP

8.32%

VR Adviser, LLC

7.38%

RA Capital Management, LP

7.03%

Millennium Management LLC

6.59%

其他

49.07%

持股股东

占比

The Column Group LP

21.60%

StemPoint Capital LP

8.32%

VR Adviser, LLC

7.38%

RA Capital Management, LP

7.03%

Millennium Management LLC

6.59%

其他

49.07%

股东类型

持股股东

占比

Venture Capital

45.48%

Hedge Fund

17.56%

Investment Advisor

13.43%

Investment Advisor/Hedge Fund

4.36%

Corporation

3.57%

Endowment Fund

2.16%

Research Firm

1.33%

Individual Investor

0.57%

其他

11.53%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

6.16M

71.83%

+31.92K

2025Q2

5.88M

68.70%

+2.83M

2025Q1

5.89M

68.82%

+2.82M

2024Q4

2.77M

85.24%

-182.72K

2024Q3

2.45M

79.78%

-789.59K

2024Q2

2.67M

92.21%

-363.75K

2024Q1

1.51M

74.09%

-612.70K

2023Q4

1.55M

75.80%

-569.05K

2023Q3

1.40M

67.10%

-482.07K

2023Q2

1.37M

65.24%

-770.64K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Column Group LP

1.50M

17.5%

Jun 30, 2025

StemPoint Capital LP

686.54K

8.01%

+445.71K

+185.08%

Jun 30, 2025

VR Adviser, LLC

632.93K

7.39%

Jun 30, 2025

RA Capital Management, LP

602.63K

7.03%

-76.50K

-11.27%

Jun 30, 2025

5AM Ventures

310.00K

3.62%

Jun 30, 2025

Access Industries, Inc.

306.00K

3.57%

+306.00K

Mar 24, 2025

The Vanguard Group, Inc.

218.95K

2.55%

+150.92K

+221.86%

Jun 30, 2025

Vivo Capital, LLC

260.00K

3.03%

Jun 30, 2025

Stonepine Capital Management, LLC

306.03K

3.57%

+20.25K

+7.08%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.01%

Dimensional US Core Equity 1 ETF

iShares Micro-Cap ETF

占比0.01%

Dimensional US Core Equity 1 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Dec 12, 2023

Merger

15→1

Dec 12, 2023

Merger

15→1

Dec 12, 2023

Merger

15→1

Dec 12, 2023

Merger

15→1

公告日期

类型

比率

Dec 12, 2023

Merger

15→1

Dec 12, 2023

Merger

15→1

Dec 12, 2023

Merger

15→1

Dec 12, 2023

Merger

15→1

常见问题

Surrozen Inc的前五大股东是谁？



Surrozen Inc 的前五大股东如下：
The Column Group LP持有股份：1.50M，占总股份比例：17.50%。
StemPoint Capital LP持有股份：686.54K，占总股份比例：8.01%。
VR Adviser, LLC持有股份：632.93K，占总股份比例：7.39%。
RA Capital Management, LP持有股份：602.63K，占总股份比例：7.03%。
5AM Ventures持有股份：310.00K，占总股份比例：3.62%。